This Pill Could Hold The Key To Stopping The SARS-CoV-2 Pandemic

Immunic Therapeutics - 1 minute read

  • IMU-838, a DHODH Inhibitor taken in tablet form
  • Demonstrated antiviral activity against SARS-CoV-2
  • Attractive pharmacokinetic, safety and tolerability profile and, to date, has already been tested in about 650 individuals.
  • Clinical trials for COVID-19 scheduled to start this month

“The broad antiviral activity of IMU-838 has been well documented and preclinical testing affirms the antiviral activity of IMU-838 against SARS-CoV-2.

As a result, we are exploring the initiation of a phase 2 clinical trial to determine if IMU-838 could be a meaningful therapeutic option for the current worldwide pandemic caused by COVID-19 and potential future pandemic threats,”

 Daniel Vitt, Ph.D. – CEO, Immunic

10 months ago from Immunic Therapeutics's press release via